Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-03 05:28:46 - browse：1529

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： New details revealed about Purdue's marketing of OxyContin

WSS

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Meadows told special counsel he could not recall Trump ever declassifying Mar

Hilary expected to bring catastrophic, life

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Living with Hashimoto's and celiac disease, and med school, too

CDC says it’s too soon to assess risk posed by Covid subvariant

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

Beware the threat of staffing cuts at the CDC

United colonoscopy coverage change 'may cost lives,' doctors say

Wegovy improves function in certain heart failure patients

Trump demands the U.S. pay no more for drugs than other countries … again

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Affirmative action in medical school literally saved lives

Republicans love RFK Jr. What's that tell us about health in 2024?

New air purifier tech could be key to improving indoor air quality

People can get long Covid without testing positive for virus: Study

focus

Health officials lay out plans to cope with respiratory virus season

National associations that represent hospice owe an apology

Intellia plays down concerns on accidental germline transmission

The pain doctors face in trying to build their families

Can U.S. cancer drug shortages be fixed?

Wegovy improves function in certain heart failure patients

leisure time

focus

hotspot

explore